טוען...
Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer
BACKGROUND: Bevacizumab has become standard of care as first-line treatment of metastatic colorectal cancer (mCRC), after proving increased response rates and improvement in survival outcomes. Hypertension (HTN) is a common complication of the treatment with bevacizumab and, owing to its close relat...
שמור ב:
הוצא לאור ב: | ESMO Open |
---|---|
Main Authors: | , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
BMJ Publishing Group
2016
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5070256/ https://ncbi.nlm.nih.gov/pubmed/27843607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000045 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|